Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 15 days ago
2	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Oral Sulopenem Etzadroxil and Probenecid for Uncomplicated Urinary Tract Infections - 18 days ago FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 2 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 3 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago Bulevirtide in Combination With PegInterferon Results In Undetectable Hepatitis D RNA Post-Treatment - 4 months ago FDA Grants Accelerated Approval for Elafibranor as Treatment of Primary Biliary Cholangitis - 5 months ago FDA Approves Rilpivirine for Treatment of HIV for Pediatric Patients 2 and Older - 8 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 9 months ago FDA Grants Fast Track Designation to Bepirovirsen for Chronic Hepatitis B - 9 months ago Prior Authorizations Pose Barrier to Access for HIV Preexposure Prophylaxis - 12 months ago FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis - about 1 year ago Lenacapvir Demonstrates Small Margin of Resistance for Those Heavily Treated With HIV - about 1 year ago
3	Katherine Kahn MedPage Today Physician-Scientist. Studies Long Covid. United States medicineLong Covid	Molnupiravir May Offer Modest 6-Month Benefits for High-Risk COVID Patients - 2 months ago Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients - 7 months ago Why Aren't More Doctors Prescribing Paxlovid to High-Risk Patients? - 10 months ago Paxlovid May Not Be Associated With Lower Long COVID Risk, Survey Suggests - 10 months ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug - 2 months ago
5	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Novel Agent Reduces Monthly Migraine Days - 2 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 8 months ago STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV - 9 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - 12 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - about 1 year ago
7	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	Antiviral used for mpox no better than placebo, NIH says - 3 months ago STAT+: For unlucky mountaineers, tundra explorers, and the unhoused, a new drug could avert the ravages of frostbite - 9 months ago
8	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	A potential MS ‘game changer’ could bring more safety to the table — even against viruses - 3 months ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - 8 months ago
9	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	2-Drug Regimen Shows Comparable Effectiveness With 3-Drug Regimen to Treat HIV-1 - 3 months ago The Use of Nirmatrelvir or Molnupiravir Could Prevent Mortality in Severe COVID-19 - about 1 year ago
10	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy - 5 months ago

Journalists covering molnupiravir